• Pulmonary Hypertension Association



PAH is difficult to treat, but nowadays there are several groups of drugs that significantly extend the lifespan and improve its quality. Since PH is a progressive disease, then the health status, which was before the illness, cannot be recovered, but with pharmacological therapy may halt its progression.

In Latvia pharmacologically therapy, as elsewhere in the world, is available only for PAH patients, but medicine for other four subtypes of PH has not yet been discovered.

There are three drug groups now available worldwide that pathogenetically influence the disease -prostanoid antagonists, endothelin receptor antagonists and phosphodiesterase V inhibitors. In Latvia available pathogenic treatment is phosphodiesterase V inhibitor – sildenafil (Revatio) or endothelin receptor antagonist –ambrisentan (Volibris), in some cases, combined therapy should be used.

Treatment for patients with specific forms of PH caused by chronic pulmonary artery embolism is also available. In this case, the only effective way of treatment is pulmonary endarterectomy.

Pathogenic PAH therapy should be administered in specialized centres. Latvian Centre of Cardiology has PAH patient operating record from 2007. During this period, 52 patients have received pathogenetic specific therapy for PAH.

Patients suspected of pulmonary arterial hypertension should be referred to Latvian Centre of Cardiology, where necessary investigations and treatment will be carried out if needed. It is also possible to consult a doctor at the Latvian Centre of Cardiology in case of unclear pulmonary hypertension.

Opportunity To Support

Checking Account: Swedbank LV82HABA0551032669984
Registration. No. 40008181693